Syapse Precision Medicine
by Syapse
· Based in United States →
— Advancing real-world care to extinguish the fear and burden of serious disease.
Overview
Syapse Precision Medicine is an AI tool designed to support the clinical implementation of precision oncology. It is primarily for oncologists and healthcare systems, including academic and community cancer centers. [3, 7, 9]
- What it does: The platform integrates clinical and genomic data to provide insights at the point of care. [3, 8, 9] It aggregates various patient data, including health history, medical records, cancer status, lab results, radiology, pathology, molecular, genomic, and treatment data. [11] Syapse also functions as a real-world evidence company, partnering with health systems, life sciences companies, and regulators. [1]
- Who it is for: The tool is intended for healthcare providers, specifically oncologists, within academic and community health systems. [3, 7, 9] It supports the entire cancer care journey, from prevention and diagnosis to treatment and survivorship. [9]
- How it fits a clinical or practice workflow: Syapse Precision Medicine integrates with existing electronic medical record (EMR) systems, allowing oncologists to access the platform within their clinical workflow. [9, 11] It facilitates decision support by enabling clinicians to review cases, track outcomes, and participate in virtual tumor boards. [4, 8] The platform also assists in identifying patients eligible for clinical trials and streamlining drug procurement. [4, 7]
- Notable capabilities: Key capabilities include clinical and genomic data integration, decision support, care coordination, and quality improvement. [3] It enables the use of real-world evidence to inform treatment decisions and supports the development of observational research analytics. [1, 7, 12] Syapse also offers applications for NGS diagnostic informatics, including Syapse Oncology, Syapse MDx, and Syapse PGx, which cover the workflow from patient sample to physician’s report. [2]
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
What Physicians Need to Know
Key Capabilities
Syapse Precision Medicine Platform is a comprehensive software suite for clinical implementation of precision medicine in oncology. It integrates clinical and genomic data, provides decision support, facilitates care coordination, and supports quality improvement at the point of care. The platform also includes features for patient management, reporting and analytics, clinical data repository, patient engagement, customizable dashboards, workflow automation, interoperability, health management, risk stratification, real-time notifications, secure messaging, appointment scheduling, compliance tracking, data security, mobile access, telehealth support, customizable reports, marketing automation, physician management, audience targeting, and medical history records.
Clinical Utility
Syapse's platform helps physicians understand complex molecular data and make informed treatment selections. It streamlines the Molecular Tumor Board process and enables a learning health system by capturing treatments and outcomes to build a real-world evidence database for future patient care. The platform assists in matching patients to clinical trials and provides a unified, longitudinal view of patient data, including clinical, pathology, radiology, treatment, and molecular information.
Integration Options
Syapse integrates data from various sources, including electronic medical records (EMRs), molecular testing labs (both internal and external), drug administration systems, pathology, and radiology. It also integrates with genomic testing services like Biotheranostics' CancerType ID and Breast Cancer Index. The platform is designed to achieve interoperability between health systems.
Compliance Status
Syapse works with the FDA's Oncology Center of Excellence to explore the use of real-world evidence to support regulatory decisions, focusing on regulatory suitability of RWE from multi-source approaches, real-world endpoints, and incorporating patient-reported outcomes. They also collaborate on developing real-world evidence standards to accelerate therapies to market.
Pricing Model
Detailed pricing for Syapse is available upon request.
User Experience
Syapse focuses on presenting complex data in an easy-to-use interface for clinicians at the point of care, aiming to fit into and enhance physician workflows through software automation. The platform provides a central place for physicians to view all relevant patient information.
Support Quality
Syapse provides email support.
Implementation Complexity
Implementing precision medicine with health IT tools is a complex undertaking, involving extensive data integration from various systems. The high cost and complexity of implementation, including interoperability issues with existing infrastructure, are noted challenges in the precision medicine software market.
Evidence Base
Syapse is a real-world evidence company that partners with health systems, life sciences companies, and regulators. They utilize a proprietary 4-branch quality control program to ensure the quality and consistency of data curated into their Real-World Evidence (RWE) platform, achieving an overall average accuracy rate of 97.0% in patient cases reviewed. Studies have demonstrated that precision medicine, as supported by Syapse, can improve progression-free survival and reduce costs in certain patient populations.
Physician Tip
Syapse Precision Medicine offers a centralized platform to integrate diverse clinical and genomic data, which can significantly enhance decision-making at the point of care for oncology patients. Leverage the decision support tools and the unified patient record to gain a holistic view of each patient's profile. Participate in the learning health network to contribute to and benefit from real-world evidence, which can inform future treatment strategies and potentially identify suitable clinical trials. Be aware that while the platform aims to streamline workflows, initial implementation may involve a learning curve due to the complexity of integrating various data sources.
Syapse is designed for extensive data integration, pulling information from EHRs, molecular testing labs, drug administration systems, pathology, and radiology. It also supports integration with specific genomic tests. The platform's strength lies in its ability to create interoperability across disparate health systems, fostering a network for shared learning and research in oncology. Syapse Holdings was acquired by N-Power Medicine in late 2024, and the Syapse brand has since been retired, with syapse.com redirecting to npowermedicine.com.
Details
| Category | Oncology AI |
| Pricing | Unknown |
| Deployment | Cloud-based platform. |
| Data Export | Unknown |
| Compliance | |
| BAA Available | Unknown |
| HIPAA Compliant | Unknown |
| FDA Status | Unknown |
| Integrations | |
| EHR | Not specified |
| Specialties | Hematology, Oncology |
What the Web Says
Syapse Precision Medicine is a data analysis software that uses advanced analytics and machine learning to help healthcare organizations extract insights from clinical and molecular data, particularly in cancer care. The platform aims to improve patient care and treatment outcomes by providing personalized treatment recommendations, predicting patient outcomes, and optimizing clinical decision-making. Syapse works with health systems, life sciences companies, and regulators to utilize real-world evidence for improving cancer patient outcomes, establishing one of the largest networks for precision medicine in oncology.
Overall: MixedStrengths
- Leverages advanced analytics and machine learning for valuable insights from clinical and molecular data.
- Provides personalized treatment recommendations and predicts patient outcomes.
- Offers advanced data integration capabilities, aggregating data from various sources like EHRs, genomics, and lab tests.
- Supports molecular tumor boards, streamlines drug procurement, and facilitates patient matching for clinical trials.
- Enables physicians to contextualize rare patient cases within larger populations for better treatment decisions.
- Has a clear sense of purpose and offers time and location flexibility for employees.
Limitations
- Some employee reviews mention a toxic work environment, constant ridicule, and intimidation by managers.
- Concerns about job security and advancement, pay and benefits, and management have been raised by employees.
- Product has been described as providing no value with useless data and unreliable PMO by some employees.
- Ambiguity in product, requirements, expectations, and timelines, making a sense of achievement difficult for some employees.
- Work-life balance and overall culture ratings are relatively low in some employee reviews.
- The Syapse brand has been retired, and the website redirects to npowermedicine.com, indicating a potential acquisition or rebranding.
Based on reviews from: SoftwareWorld, Comparably, Indeed.com, APIs.io Providers, AJMC, The Cancer Letter
Last updated: 2026-10-25
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Syapse Precision Medicine
Press & Coverage
BusinessWire
N-Power Medicine Acquires Syapse to Expand Its Next-Generation Community-Based Network for Oncology Clinical Research and Clinical Trials
N-Power Medicine acquired Syapse Holdings Inc. to expand its network for oncology clinical research and trials, integrating Syapse's community-based health systems, over 1,000 oncologists, and its data and technology. This acquisition aims to revolutionize community-based patient care by expanding access to clinical trials and life-saving innovations.
2025-01
GlobeNewswire
Syapse Expands Oncology Real-World Data Offerings with Introduction of Syapse Cohorts: Essentials
Syapse launched 'Syapse Cohorts: Essentials,' a new real-world data offering designed to provide cancer researchers and life sciences companies with foundational datasets across more than 50 tumor types. This expands Syapse's existing 'Enriched Cohorts' offering, aiming to facilitate more personalized and impactful cancer research and treatments.
2024-05
Clinical Trials Arena
FDA renews Syapse collaboration to use real-world data in oncology
The US FDA renewed a four-year collaboration agreement with Syapse, focusing on evaluating real-world data study designs and methods to inform regulatory objectives in oncology. This partnership aims to explore the potential uses of real-world data in regulatory decision-making, building on previous work examining health disparities and treatment impacts.
2023-12
Revelation Partners
Syapse Announces $35 Million Growth Investment with Innovatus Capital Partners to Expand Delivery of Real-World Evidence Through Syapse’s Learning Health Network
Syapse secured $35 million in growth funding led by Innovatus Capital Partners, with participation from existing investors, to expand its focus on providing real-world insights and improving outcomes for cancer patients. This investment will help Syapse further deliver real-world evidence through its Learning Health Network.
2022-07
GlobeNewswire
Syapse and Pfizer Renew Strategic Collaboration to Accelerate Precision Medicine Through Real-World Evidence
Syapse and Pfizer renewed their strategic collaboration to accelerate precision medicine using real-world evidence from the Syapse Learning Health Network. This partnership aims to understand treatment patterns, disease progression, and the overall treatment journey in oncology, informing and enhancing clinical studies.
2021-03
PR Newswire
Amgen and Syapse Form Precision Medicine Alliance in Oncology
Amgen and Syapse announced a precision medicine collaboration in oncology to develop observational research analytics and assess treatment outcomes for unmet needs. This alliance will identify eligible patients for Amgen-sponsored clinical trials within the Syapse Learning Health Network and bring these trials to community health systems.
2019-05
PR Newswire
Syapse Raises $25 Million Series C Round Led by Ascension Ventures to Expand Precision Medicine
Syapse completed the first close of a $25 million Series C funding round led by Ascension Ventures, with participation from existing investors. The funding will be used to expand the Syapse Precision Medicine Platform in community health systems, focusing on integrating clinical and genomic data, providing treatment guidance, and measuring patient outcomes.
2016-01
The Cancer Letter
Caris Life Sciences and Syapse to collaborate on genomic information
Caris Life Sciences and Syapse announced a collaboration to combine molecular and genomic information with clinical treatment and outcomes data across the Caris Centers of Excellence for Precision Medicine Network. This integration aims to provide a real-time clinical decision support system for more informed treatment decisions.
2015-12
Videos
Product demos, reviews, and walkthroughs for Syapse Precision Medicine.
Transforming patient care through precision medicine.
Syapse
PMWC16 Panel "Clinical Implementation of Precision Medicine Programs"
Syapse
Jonathan Hirsch, on precision medicine software helping oncologists make therapeutic decisions
OBRoncology
Customer Story: Intermountain Healthcare
Syapse
Jonathan Hirsch: What is Unique about Syapse
Healthy Dialogues
Precision Medicine Synapse
From Testing to Targeted Treatment Program (FT3)
Frequently Asked Questions
Syapse Precision Medicine is designed to integrate with existing EHR systems and oncology workflows to streamline data collection and analysis. It aims to pull relevant patient data, including genomic information, clinical history, and treatment outcomes, into a unified platform for a comprehensive view. This integration helps physicians access actionable insights directly within their familiar clinical environment, minimizing disruption and improving efficiency.
Syapse Precision Medicine adheres to stringent compliance and data privacy regulations, including HIPAA, to protect sensitive patient information. The platform employs robust security protocols, data encryption, and access controls to ensure the confidentiality and integrity of health data. Syapse also works with institutions to establish data governance frameworks that align with their specific compliance requirements.
While powerful, AI in oncology, including Syapse Precision Medicine, has limitations such as potential biases in algorithms, the need for high-quality data, and the interpretability of complex AI models. Syapse addresses these by focusing on explainable AI, ensuring transparency in how recommendations are generated, and continuously validating its algorithms with diverse datasets. The platform also emphasizes that AI serves as a decision support tool, with final clinical decisions remaining with the physician.
Syapse Precision Medicine differentiates itself through its focus on real-world evidence, comprehensive data integration, and collaborative network of healthcare providers. Unlike some in-house solutions that may have limited data sets, Syapse aggregates data across multiple institutions to provide broader insights. Compared to other platforms, Syapse emphasizes a holistic view of the patient journey, from diagnosis to treatment and outcomes, facilitating more informed decision-making.
The pricing model for Syapse Precision Medicine typically involves a subscription-based approach, which can vary depending on the size of the oncology practice, the scope of services utilized, and the level of data integration required. Syapse often offers different tiers or customized solutions to meet the specific needs and budgets of various healthcare institutions. Specific pricing details are usually discussed directly with potential clients to tailor a plan.
Syapse Precision Medicine assists in clinical trial matching by leveraging its comprehensive patient data and advanced analytics to identify eligible patients for relevant trials. The platform can analyze a patient's genomic profile, clinical history, and treatment progression against trial inclusion criteria. This capability helps physicians efficiently identify and connect patients with appropriate novel therapies and research opportunities, expanding treatment options.
Syapse provides comprehensive training and ongoing support to physicians and their oncology teams to ensure effective utilization of the Precision Medicine platform. This typically includes initial onboarding sessions, educational resources, and dedicated technical support. Syapse aims to empower healthcare professionals to confidently navigate the platform, interpret insights, and integrate the technology seamlessly into their clinical practice.
Suggest an Edit → | Report an issue
| Last Verified: 2026-04-22 | First Added: 2026-04-22
Investors who backed Syapse Precision Medicine
Funded through the company that built this tool.
